| |
| |
|
| Insider
Information: |
Amado Rafael |
| Relationship: |
Director |
| City: |
Malvern |
| State: |
PA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
622,015 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$476,633 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
622,015 |
|
|
| Total
Value |
$476,633 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -37.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Adaptimmune Therapeutics PLC |
ADAP |
President, R&D |
2019-08-06 |
17,237 |
|
0 |
Premium* |
|
|
Allogene Therapeutics, Inc. |
ALLO |
|
2022-10-07 |
541,946 |
2019-09-03 |
0 |
Premium* |
|
|
Zai Lab Ltd |
ZLAB |
|
2024-04-04 |
23,532 |
2022-12-30 |
0 |
Premium* |
|
|
Poseida Therapeutics, Inc. |
PSTX |
Director |
2023-05-01 |
39,300 |
2023-05-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ZLAB |
Zai Lab Ltd |
See Remarks |
• • – |
2024-04-04 |
4 |
S |
$15.67 |
$30,594 |
D/D |
(1,952) |
23,532 |
0 |
% |
|
| ZLAB |
Zai Lab Ltd |
See Remarks |
• • – |
2024-04-03 |
4 |
OE |
$15.90 |
$85,717 |
D/D |
5,391 |
25,484 |
0 |
- |
|
| ZLAB |
Zai Lab Ltd |
See Remarks |
• • – |
2024-03-15 |
4 |
AS |
$18.86 |
$47,980 |
D/D |
(2,544) |
20,093 |
0 |
% |
|
| ZLAB |
Zai Lab Ltd |
See Remarks |
• • – |
2024-01-02 |
4 |
S |
$26.30 |
$509,169 |
D/D |
(19,363) |
22,637 |
0 |
% |
|
| ZLAB |
Zai Lab Ltd |
See Remarks |
• • – |
2023-12-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
42,000 |
42,000 |
0 |
- |
|
| PSTX |
Poseida Therapeutics, Inc... |
Director |
– • – |
2023-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
39,300 |
39,300 |
0 |
- |
|
| ZLAB |
Zai Lab Ltd |
See Remarks |
• – – |
2022-12-30 |
4 |
A |
$0.00 |
$0 |
D/D |
126,000 |
126,000 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D |
• • – |
2022-10-07 |
4 |
D |
$11.83 |
$100,099 |
D/D |
(8,464) |
541,946 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D |
• • – |
2022-10-07 |
4 |
A |
$0.00 |
$0 |
D/D |
19,120 |
550,410 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D |
• • – |
2022-10-03 |
4 |
D |
$11.06 |
$99,201 |
D/D |
(8,968) |
531,290 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2022-08-02 |
4 |
AS |
$11.97 |
$23,940 |
D/D |
(2,000) |
540,257 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2022-07-05 |
4 |
AS |
$11.44 |
$22,880 |
D/D |
(2,000) |
542,257 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2022-06-21 |
4 |
AS |
$11.18 |
$22,360 |
D/D |
(2,000) |
544,257 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2022-05-19 |
4 |
S |
$7.40 |
$85,092 |
D/D |
(11,500) |
546,257 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2022-03-23 |
4 |
A |
$0.00 |
$0 |
D/D |
237,358 |
557,477 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2022-03-15 |
4 |
S |
$7.71 |
$39,848 |
D/D |
(5,169) |
320,119 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2021-10-01 |
4 |
S |
$24.35 |
$280,185 |
D/D |
(11,507) |
323,928 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2021-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
200,534 |
335,435 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2021-03-26 |
4 |
A |
$0.00 |
$0 |
D/D |
24,866 |
134,901 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2021-03-15 |
4 |
S |
$38.05 |
$106,471 |
D/D |
(2,798) |
110,035 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2020-10-07 |
4 |
AS |
$39.40 |
$651,515 |
D/D |
(16,538) |
111,677 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2020-10-01 |
4 |
S |
$36.37 |
$354,662 |
D/D |
(9,752) |
128,215 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2020-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
30,800 |
135,962 |
0 |
- |
|
| ALLO |
Allogene Therapeutics, In... |
EVP of R&D and CMO |
• – – |
2019-09-03 |
4 |
A |
$0.00 |
$0 |
D/D |
105,162 |
105,162 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
President, R&D |
• – – |
2019-08-06 |
4 |
S |
$2.06 |
$22,749 |
D/D |
(11,043) |
17,237 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
